Motley Fool Asset Management’s Myriad Genetics MYGN Stock Holding History

Motley Fool Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-77,000	Closed	-$2.36M	–	76
2016 Q2	$2.36M	Hold	77,000	–	–	0.51%	61
2016 Q1	$2.88M	Hold	77,000	–	–	0.6%	63
2015 Q4	$3.32M	Hold	77,000	–	–	0.67%	57
2015 Q3	$2.89M	Hold	77,000	–	–	0.57%	59
2015 Q2	$2.62M	Hold	77,000	–	–	0.46%	67
2015 Q1	$2.73M	Buy	77,000 +22,000	+40%	+$787K	0.48%	63
2014 Q4	$1.87M	Buy	55,000 +30,000	+120%	+$1.06M	0.35%	70
2014 Q3	$946K	Buy	+25,000	New	+$933K	0.2%	81

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Motley Fool Asset Management's MYGN Position: Q3 2016 in Review

Motley Fool Asset Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 77,000 shares — an estimated $2.36M sold.

Motley Fool Asset Management first reported a position in MYGN in Q3 2014 and held it in 8 quarters. The position peaked at $3.32M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Motley Fool Asset Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Motley Fool Asset Management sold 77,000 Myriad Genetics shares in Q3 2016, an estimated $2.36M.
Motley Fool Asset Management first reported a position in Myriad Genetics in Q3 2014 and held it in 8 quarters.
Motley Fool Asset Management's Myriad Genetics position peaked at $3.32M in Q4 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Motley Fool Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.